ACADIA Pharmaceuticals Inc. (ACAD) has a consensus analyst rating of Buy, based on 37 analysts covering the stock. Of those, 26 recommend buying, 10 recommend holding, and 1 recommend selling.
The analyst consensus price target for ACAD is $34.78, representing a +57.9% upside from the current price of $22.02. Price targets range from a low of $29.00 to a high of $40.00.
